RxDoctor Payments Data

Cristina Garcia, MD

Family Medicine · Pico Rivera, CANPI 1326391004

Payments from drug & device makers

$1,772in general payments, 2019–2025

Across 45 payments — averaging $39.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$510
  • Amgen$375
  • GSK$244
  • Lilly USA, LLC$207
  • AstraZeneca$125
  • Radius Health, Inc.$125
  • plus $186 from 2 others

What the payments were for

  • Food & beverage$1,772100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,772 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$13,449
Medicare patients
49
Services billed
215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$110,526
TrulicityDulaglutide37$41,912
MounjaroTirzepatide35$33,677
EliquisApixaban15$21,187
JanuviaSitagliptin Phosphate12$17,435
RybelsusSemaglutide14$13,261
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$7,459
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,672
Albuterol Sulfate HfaAlbuterol Sulfate74$1,841
Losartan Potassium127$1,317
Levothyroxine Sodium69$1,306
Atorvastatin Calcium165$1,084
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen51$1,005
Omeprazole101$764
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$510$123,787109 claims
Lilly USA, LLCTrulicity, Mounjaro$207$75,59072 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Pico Rivera

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →